Alkermes plc (ALKS)
NASDAQ·Healthcare·Biotechnology
$34.28
+1.63%
Mkt Cap $5.62B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 25, 2026 | $378.94M | $384.55M | +1.48% | $0.43 | $0.34 | -20.93% | — | — |
| Q4 2025 Oct 28, 2025 | $379.89M | $394.19M | +3.76% | $0.42 | $0.49 | +16.67% | — | — |
| Q3 2025 Jul 29, 2025 | $354.51M | $390.66M | +10.20% | $0.41 | $0.52 | +26.83% | — | — |
| Q2 2025 May 1, 2025 | $302.91M | $306.51M | +1.19% | $0.25 | $0.13 | -48.92% | — | — |
| Q1 2025 Feb 12, 2025 | $379.42M | $429.99M | +13.33% | $0.81 | $1.04 | +28.40% | — | — |
| Q4 2024 Oct 24, 2024 | $381.36M | $378.14M | -0.84% | $0.74 | $0.72 | -2.70% | — | — |
| Q3 2024 Jul 24, 2024 | $382.82M | $399.13M | +4.26% | $0.70 | $0.70 | +0.00% | — | — |
| Q2 2024 May 1, 2024 | $393.35M | $350.37M | -10.93% | $0.59 | $0.44 | -25.42% | — | — |
| Q1 2024 Feb 15, 2024 | $377.00M | $377.48M | +0.13% | $0.46 | $0.48 | +4.35% | — | — |
| Q4 2023 Oct 25, 2023 | $362.15M | $380.94M | +5.19% | $0.44 | $0.64 | +45.45% | — | — |
| Q3 2023 Jul 26, 2023 | $363.87M | $617.40M | +69.68% | $0.48 | $0.55 | +14.58% | — | — |
| Q2 2023 Apr 26, 2023 | $580.89M | $287.60M | -50.49% | $0.00 | $0.01 | +173.97% | — | — |
| Q1 2023 Feb 16, 2023 | $278.69M | $304.67M | +9.32% | $0.05 | $0.14 | +180.00% | — | — |
| Q4 2022 Nov 2, 2022 | $271.41M | $252.36M | -7.02% | $0.03 | $0.02 | -34.06% | — | — |
| Q3 2022 Jul 27, 2022 | $268.97M | $276.22M | +2.70% | $0.01 | $0.06 | +740.34% | — | — |
| Q2 2022 Apr 27, 2022 | $256.02M | $278.55M | +8.80% | $0.01 | $0.12 | +1066.18% | — | — |
| Q1 2022 Feb 16, 2022 | $306.55M | $324.46M | +5.84% | $0.13 | $0.23 | +76.92% | — | — |
| Q4 2021 Oct 27, 2021 | $242.67M | $294.14M | +21.21% | $0.08 | $0.14 | +75.00% | — | — |
| Q3 2021 Jul 28, 2021 | $299.70M | $303.72M | +1.34% | $0.12 | $0.30 | +150.00% | — | — |
| Q2 2021 Apr 28, 2021 | $233.87M | $251.43M | +7.51% | -$0.05 | $0.11 | +320.00% | — | — |